

This is the author-created version of the following work:

Liu, Zhiwei, Yu, Kelly J., Coghill, Anna E, Brenner, Nicole, Cao, Su-Mei, Chen, Chien-Jen, Chen, Yufeng, Doolan, Denise, Hsu, Wan-Lun, Labo, Nazzarena, Middeldorp, Jaap M., Miley, Wendell, Simon, Julia, Wang, Cheng-Ping, Waterboer, Tim, Whitby, Denise, Xie, Shang-Hang, Ye, Weimin, and Hildesheim, Allan (2019) *Multilaboratory assessment of Epstein-Barr virus serologic assays: the case for standardization. Journal of Clinical Microbiology, 57 (11) .*

Access to this file is available from:

<https://researchonline.jcu.edu.au/61214/>

Copyright © 2019 American Society for Microbiology.

Please refer to the original source for the final version of this work:

<https://doi.org/10.1128/JCM.01107%2D19>

1 **Multi-laboratory assessment of EBV serologic assays: the case for**
2 **standardization**

3 Zhiwei Liu ^{1*}, Kelly J. Yu ¹, Anna E Coghil ^{1,2}, Nicole Brenner ³, Su-Mei Cao ⁴, Chien-Jen Chen ⁵,
4 Yufeng Chen ⁶, Denise L. Doolan ⁷, Wan-Lun Hsu ⁵, Nazzarena Labo ⁸, Jaap M. Middeldorp ⁹, Wendell
5 Miley ⁸, Julia Simon ^{3,10}, Cheng-Ping Wang ¹¹, Tim Waterboer ⁹, Denise Whitby ⁸, Shang-Hang Xie ⁴,
6 Weimin Ye ⁶, Allan Hildesheim ¹

- 7 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- 8 2. Cancer Epidemiology Program, Division of Population Sciences, H. Lee Moffitt Cancer Center &
9 Research Institute, Tampa, FL, USA
- 10 3. Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg,
11 Germany
- 12 4. Department of Cancer Prevention Research, Sun Yat-sen University Cancer Center, State Key
13 Laboratory of Oncology in South China; Collaborative Innovation Center Medicine, Guangzhou,
14 China.
- 15 5. Genomics Research Center, Academia Sinica, Taipei, Taiwan
- 16 6. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 17 7. Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James
18 Cook University, Cairns, Australia
- 19 8. Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD
- 20 9. Department of Pathology, VU University Medical Center, Amsterdam, Netherlands
- 21 10. Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
- 22 11. Department of Otolaryngology, National Taiwan University Hospital and College of Medicine,
23 Taipei, Taiwan

24 **Corresponding Author:**

25 Zhiwei Liu, PhD,

26 Division of Cancer Epidemiology and Genetics, National Cancer Institute,

27 9609 Medical Center Drive, Rockville, MD 20850

28 Phone: +0012402766726, Email address: zhiwei.liu@nih.gov

29 **Declaration of Interests.** Dr. Middeldorp received payments as Owner-CEO of Cyto-Barr BV. Other

30 authors declare no conflict of interest.

31 **Word count:** abstract 242; main text 2657

32

33 **Abstract**

34 **Background**

35 IgA antibodies targeting Epstein-Barr virus (EBV) have been proposed for screening for nasopharyngeal
36 carcinoma (NPC). However, methods vary, and antigens used in these assays differ considerably between
37 laboratories.

38 **Methods**

39 To enable formal comparisons across a range of established EBV serology assays, we created a panel of
40 66 pooled serum and 66 pooled plasma samples generated from individuals with a broad range of IgA
41 antibody levels. Aliquots from these panels were distributed to six laboratories and tested by 26 assays
42 measuring antibodies against VCA, EBNA1, EA-EBNA1, Zta, or EAd antigens. We estimated the
43 correlation between assay-pairs using Spearman coefficients (continuous measures) and percentage
44 agreement (positive versus negative using pre-defined positivity cutoffs by each assay
45 developer/manufacturer).

46 **Results**

47 While strong correlations were observed between some assays, considerable differences were also noted,
48 even for assays that targeted the same protein. For VCA-IgA assays in serum, two distinct clusters were
49 identified, with the median Spearman coefficient of 0.41 (range: 0.20 – 0.66) across these two clusters.
50 EBNA1-IgA assays in serum grouped into a single cluster with the median Spearman coefficient of 0.79
51 (range: 0.71 – 0.89). Percentage agreements varied broadly for both VCA-IgA (12% – 98%) and
52 EBNA1-IgA (29% – 95%) assays in serum. Moderate-to-strong correlations were observed across assays
53 in serum that targeted other proteins (correlations range: 0.44 – 0.76). Similar results were noted for
54 plasma.

55 **Conclusion**

56 Standardization of EBV serology assays is needed to allow for comparability of results obtained in
57 different translational research studies across laboratories and populations.

58

59

60 Introduction

61 Assays that measure antibody responses to Epstein-Barr virus (EBV) have become increasingly
62 important tools for studying and diagnosing nasopharyngeal carcinoma (NPC) and other research (1, 2).
63 Several studies have shown that individuals with elevated levels of antibody responses against EBV
64 antigens (particularly IgA responses) are at increased risk for the development of NPC (3-15). In NPC
65 endemic areas such as Southern China, EBV IgA antibody testing has been proposed for general
66 population screening to triage individuals to further clinical evaluation aiming at the early detection and
67 treatment of NPC (4, 7, 16, 17). However, recent studies have elucidated the underlying (epitope)
68 complexity of anti-EBV antibody responses, and this needs to be considered in order to achieve
69 standardization amongst the community (2).

70 IgA antibodies against EBV capsid antigen (VCA-IgA) and EBV nuclear antigen 1 (EBNA1-IgA)
71 are the two EBV serological markers most frequently considered for screening purposes (4, 7, 16-18).
72 However, several assays that measure VCA-IgA and EBNA1-IgA exist, and efforts to standardize these
73 EBV assays have been limited, making it difficult to compare results across studies that utilize different
74 assays. To date, no studies have directly compared VCA- or EBNA1-IgA results from the various assays
75 used in different laboratories globally to define interassay agreement or to assess whether the same
76 humoral immune response is being measured by each assay. As such markers have been proposed for use
77 in NPC early-detection screening programs. Understanding the relationship between existing commercial
78 and research assays is needed to interpret the published literature. Evaluation of the correlation and
79 percentage agreement between assays represents an important initial step toward the standardization for
80 assays intended for clinical use.

81 To measure agreement between assays measuring antibodies against EBV, we conducted a study
82 in which pools of serum and plasma from individuals with a range of expected antibody levels were
83 created and blindly distributed to six different laboratories for testing. We initially focused on assays that

84 measure antibodies against VCA and EBNA1 because those are the two main EBV antigens targeted for
85 antibody tests considered for EBV screening purposes. Herein, we described the various laboratories'
86 methods and correlation/agreement between assays. For completeness, we also included assays that
87 measure antibodies against other EBV proteins (*e.g.*, early D antigen [EAd] and Zta) to understand the
88 correlations between assays that measure antibodies against these different proteins.

89 **Methods**

90 Source population

91 This panel of EBV serology standards was created by capitalizing on biospecimen resources from
92 ongoing and completed studies conducted in Taiwan (10, 19) between 1991 and 2016. Serum and plasma
93 samples were prepared within 24 hr of collection and stored frozen at -80°C until analysis. These studies
94 were reviewed/approved by the National Cancer Institute Special Studies Institutional Review Board and
95 the National Taiwan University Institutional Review Board. Written informed consent was obtained for
96 all participants.

97 Creating pools for testing

98 To create a resource with sufficient volume to permit testing by multiple assays in multiple
99 laboratories, pooling samples across individuals was required. We created both serum and plasma pools
100 with different individuals contributing samples for serum pools and plasma pools because of limited
101 specimen availability from the previous studies. To ensure that a broad distribution of IgA antibody
102 responses was retained after pooling, blood samples from individuals with similar expected IgA responses
103 were pooled whenever possible. IgA antibody titers at collection were retrieved from participants'
104 medical files or experimental records at collection, based on different IgA assays in routine clinical use at
105 the time each of the studies was conducted. Briefly, a total of 66 pooled serum samples and 66 pooled
106 plasma samples were generated from an average of two individuals (range: 1-5), of which 22 pooled
107 serum/plasma samples were created from 1) NPC cases (representing samples with potentially elevated

108 IgA antibody titers) and non-NPC cases with known high levels of IgA antibodies against EBV, 2)
109 general population controls from a previously conducted NPC case-control study (representing samples
110 expected to have low IgA antibody titers) and hospital outpatients with known low levels of IgA
111 antibodies against EBV, and 3) unaffected individuals from an ongoing NPC multiplex family study
112 (representing individuals at high risk of developing NPC).

113 Plate batching of pools

114 Participating laboratories were provided with one aliquot (range: 25µl – 150µl) of each sample
115 without knowledge of whether the sample came from high-risk or low-risk pools. We also included
116 approximately 20% randomly selected, blinded duplicate samples (N=14) to assess within-assay
117 intraclass correlation coefficients (ICCs) and coefficients of variation (CV). All samples were randomly
118 distributed on the plate and sent to participating laboratories in individual cryovials.

119 Assays performed

120 Six independent laboratories agreed to test serum and/or plasma specimens using research or
121 commercial assays (enzyme-linked immunosorbent assay [ELISA] or Luminex assays). Of the 26 assays,
122 two VCA-IgA assays (A2.1 and A2.2) and two EBNA1-IgA assays (A9.1 and A9.2) comprised
123 commercial assays purchased from the same company but tested in different laboratories with different
124 pre-defined positivity cutoffs. No special instructions were given to the laboratories regarding the
125 handling or testing of these specimens. Details of each assay, including information on sample dilution,
126 antigens targeted, amino acid sequences, and whether the assays were designed to capture IgA, IgG, or
127 IgG/IgA/IgM are provided in **Supplementary Materials** and **Supplementary Table 1**. In total, we
128 included eight assays designed to measure antibodies against VCA, of which six assays were designed to
129 detect IgA, one assay was designed to detect IgG/IgA/IgM, and one assay was designed to detect IgG.
130 Nine assays designed to measure antibodies against EBNA1, of which six assays were designed to detect
131 IgA, two assays were designed to detect IgG/IgA/IgM, and one assay was designed to detect IgG. Nine

132 assays were designed to measure antibodies against other antigens (*i.e.*, EA-EBNA1, Zta and EAd), of
133 which two assays were designed to detect IgA against EA-EBNA1 combined, four assays were designed
134 to detect antibodies against EAd (two for IgA, one for IgG/IgA/IgM and one for IgG), and three assays
135 were designed to detect antibodies against Zta (two for IgA and one for IgG/IgA/IgM).

136 Statistical Analysis

137 We first utilized the blinded duplicate pools included in our panel to estimate reproducibility of
138 the 26 assays performed as part of our effort. For each specimen type (*i.e.*, serum or plasma), assays were
139 clustered according to their Spearman correlations using unsupervised hierarchical clustering with
140 Euclidean distance and complete linkage (20). Correlation coefficients of larger than 0.7, between 0.5
141 and 0.7, and less than 0.5 were considered to be strong, modest, and weak correlations, respectively (21).
142 We also estimated percentage agreement and Kappa value between assay pairs using pre-defined
143 positivity cutoffs for IgA assays as these IgA assays have been proposed for screening for NPC
144 (**Supplementary Table 1**).

145 Analyses were performed using R Statistical Software (Foundation for Statistical Computing,
146 Vienna, Austria). All statistical tests were 2-sided, and $P < 0.05$ was considered statistically significant.

147 **Results**

148 After quality control, we excluded from further consideration six assays evaluating serum (*i.e.*,
149 Assays A18, A19, A21, A22, A23, and A24) and five evaluating plasma (*i.e.*, Assays A3, A9.2, A14,
150 A23, and A24) with ICC<0.8 or CV>20% (**Table 1**). Among assays measuring antibodies against VCA,
151 we included eight assays (six IgA, one IgG, and one IgG/IgA/IgM) for serum and seven assays (five IgA,
152 one IgG, and one IgG/IgA/IgM) for plasma. Among assays measuring antibodies against EBNA1, we
153 included nine assays (six IgA, one IgG, and two IgG/IgA/IgM) for serum and seven assays (five IgA, one
154 IgG, and one IgG/IgA/IgM) for plasma. Among assays measuring antibodies against other antigens (*i.e.*,
155 EAd and Zta), we included two assays (all IgA) for serum and six assays (three IgA, one IgG, and two

156 IgG/IgA/IgM) for plasma in the analysis. The average response levels are summarized in **Table 1** and
157 results stratified by our three pre-defined groups are shown in **Supplementary Table 2**.

158 Antibodies against VCA

159 The correlations between assays measuring antibodies against VCA in serum are presented in
160 **Figure 1A**. A total of three clusters were identified. Correlations tended to be higher within rather than
161 across immunoglobulin classes (Clusters #1 and #2 vs. Cluster #3; Cluster #3 representing IgG and
162 IgG/IgA/IgM). IgA only assays grouped into two clusters: Cluster #1 included three research assays
163 measuring the same antigen (VCA-p18; [Assays A1, A4, and A5] sequences illustrated in
164 **Supplementary Figure 1**) with a median Spearman coefficient of 0.85 (range: 0.85 – 0.87); Cluster #2
165 included two commercial assays (assays A2.1/A2.2 and A3. Assays A2.1 and A2.2 were purchased from
166 the same company but tested by two different labs) with a median Spearman coefficient of 0.71 (range:
167 0.64 – 0.97). Weak-to-moderate correlations were observed among IgA assays across Clusters #1 and #2,
168 with a median Spearman coefficient of 0.41 (range: 0.20 – 0.66). The lowest correlation was observed
169 between assays A2.2 and A5 (Spearman coefficient = 0.20).

170 Among IgA only assays, the percentage agreement for serum varied considerably from 12% - 98%
171 (Kappa values ranged from -0.03 to 0.9, **Table 2**). Higher agreements were observed between assays that
172 clustered together in **Figure 1** (e.g., between assays A2.1 and A2.2, 95%; and between assays A4 and A5,
173 98%). By contrast, lower agreements were observed between assays that clustered separately (**Figure 1**,
174 e.g., between assays A1 and A3, 12%; and between assays A3 and A5, 15%).

175 Antibodies against EBNA1

176 The correlations between assays measuring antibodies against EBNA1 in serum are presented in
177 **Figure 1B**. Again, among three clusters that were identified, correlations tended to be higher within
178 rather than across immunoglobulin classes (Cluster #1 vs Clusters #2 and #3; Clusters #2 and #3
179 representing IgG/IgA/IgM and IgG). In contrast to observations made for VCA, all IgA only assays

180 grouped into a single cluster (sequences illustrated in **Supplementary Figure 2**), with a median
181 Spearman coefficient of 0.79 (range: 0.71 – 0.89). However, a wide range of percentage agreement (29%
182 – 95%, Kappa values ranged from 0.1 to 0.9, **Table 3**) was observed for these IgA assays.

183 Antibodies against other EBV antigens (i.e., Zta and EAd)

184 To understand the correlations between assays measuring antibodies against distinct EBV
185 proteins (i.e., Zta, EAd, VCA and EBNA1,) we compared results from assays targeting Zta and EAd
186 (sequences illustrated in **Supplementary Figure 3**) against representative assays targeting VCA and
187 EBNA1. Specifically, for this evaluation we included one IgA assay for each of the two clusters
188 identified for VCA IgA (assays A1 and A2.1) and one assay from the single cluster identified for EBNA1
189 IgA (assay A8). The correlations between those assays in serum are shown in **Figure 1C**. Weak-to-
190 moderate correlations were observed for IgA assays, with a median Spearman coefficient of 0.60 (range:
191 0.44 – 0.76).

192 Results in plasma

193 Similar correlations were observed in serum as in plasma when comparisons were made across
194 assays and results are presented in **Supplementary Figure 4 and Supplementary Tables 3-4**.

195 **Discussion**

196 IgA antibodies against EBV VCA and EBNA1 have been proposed to facilitate diagnosis and
197 early detection of NPC in high incidence regions (9, 17, 18). However, there has been very little effort to
198 standardize the assays being considered for such programs and to understand the similarities and
199 differences in their performance. Herein, we report the first study to directly compare assays designed to
200 measure these antibodies. Although we observed high correlation and agreement between some assays,
201 our results demonstrate wide variability among the assays evaluated when assays were compared with
202 respect to both antibody levels and serostatus. Such variability could be caused by differences in targeted

203 antigens, detection methods, and dynamic range of assays. These findings highlight the need for more
204 formal attempts to validate and standardize EBV serology assays that are being considered or used for
205 population screening or clinical diagnosis aimed at the early detection of NPC.

206 In the present study, clear differences were observed for assays designed to detect antibodies
207 against VCA. Although a low agreement between assays designed to measure different Ig classes (IgG
208 vs. IgA) was expected (22), two distinct clusters of IgA assays were noted. For these two clusters, good
209 agreement was noted for assays contained within a cluster while poor agreement was observed for assays
210 contained across clusters. The high correlation within clusters is likely explained by sharing of
211 antigens/epitopes targeted by these assays (e.g., assays A1, A4, and A5 targeted VCA-p18, one of six
212 proteins comprising the EBV viral capsid), although in some instances (assays A2.1, A2.2, and A3) we
213 could not confirm this fact since information on target probes was not disclosed by the assay
214 developer/manufacture. The EBV VCA is a complex containing major capsid protein (p160; BcLF1),
215 small capsid protein (VCA-p18, BFRF3), scaffold protein (VCA-p40, BdRF1), tegument protein p23
216 (BLRF2), glycoproteins gp125/110 (BALF4), and gp350/220 (BLLF1) (2). The immunodominant and
217 virus-specific antigenic domain of VCA-p18 has been mapped and is located in its C-terminus (AA 110-
218 176), whereas such domain is less clear for other VCA complex proteins (2). It is expected that different
219 VCA components will contain distinct immunodominant domains, induce different levels of antibody
220 response, and have different diagnostic performance. Moving forward, reporting of probe sequences used
221 to measure EBV VCA antibodies will be important to facilitate interpretation of results across studies.

222 For EBNA1, we noted poor agreement for assays designed to detect different Ig classes but better
223 agreement for assays designed to detect IgA, suggesting that these assays target similar epitopes. In fact,
224 review of the probe sequences used to capture antibodies against EBNA1 revealed overlap across all
225 assays for AA 382-404. This is consistent with reports that an immunodominant epitope of the EBNA1
226 protein (BKRF1, the major antigenic component of the EBNA complex), is located within AA 390-450
227 (2, 13, 23). Nonetheless, it is important to note that despite the high correlation observed for EBNA1 IgA

228 assays, the range of percentage positive agreements between these assays was wide, suggesting varying
229 sensitivities or thresholds for defining a positive response. The seropositivity cut-point we applied for
230 each assay was predefined by the assay developers/manufacturers. These different assay positivity rates
231 further highlight the need for careful validation and standardization of these assays in the future.

232 The moderate correlations for assays measuring IgA antibodies against different EBV proteins
233 (VCA, EBNA1, EA_d and Zta) was included in this report for completeness and provides a useful
234 benchmark when evaluating levels of agreement for VCA and EBNA1 assays. Rates of agreement across
235 protein targets were consistent with previous findings (22). The elevated levels of anti-EBV antibodies
236 could indicate the ongoing viral lytic activity (reactivation) and a potential lack of control over the virus
237 in general. Noteworthy is the fact that levels of agreement observed across proteins (expected to be
238 modest) overlap with those noted within proteins (expected to be high for well standardized and
239 characterized assays), again highlighting the need for further assay standardization in the future.

240 Strengths of our study included carefully selected pools meant to represent the entire expected
241 range in antibody levels, direct comparison of assays using these pools, inclusion of many assays and
242 laboratories. However, our results should be interpreted in light of some limitations. First, serum and
243 plasma samples were not collected from the same individuals, which precludes us from formally
244 comparing the antibody level and its correlation between serum and plasma based on paired samples.
245 Second, information on the nature of EBV antigen used was missing for a few assays, which precludes us
246 from further exploring the factors causing variability across different assays.

247 In conclusion, using a carefully-defined panel of serum and plasma samples distributed among
248 multiple reference laboratories, we report high agreement for some assays designed to measure antibodies
249 against same EBV antigens. However, we also observed considerable variability in the agreement
250 between assays designed to measure antibodies against EBV VCA and EBNA1, both with respect to their
251 correlation and to their reported positivity rates. Our study highlights the need for more systematic
252 standardization of these assays and for the development of an international standard for measuring these

253 antibody responses in serum or plasma. Such efforts are pre-requisites for the formal evaluation and
254 quantitation of the performance of these assays in clinical practice or for population-based screening
255 aimed at the early detection of NPC in high incidence regions.

256 **Acknowledgments**

257 This research was supported by the National Cancer Institute Intramural Research Program, USA. The
258 funding organization played no role in the study design, collection, management, analysis, and
259 interpretation of the data; or preparation, review, and approval of the manuscript.

260 **Figure Legends**

261 **Figure 1.** Unsupervised hierarchical clustering based on Spearman correlation coefficient between assays
262 measuring anti-EBV antibodies in serum. **A)** Antibodies against EBV capsid antigen (VCA); **B)**
263 Antibodies against EBV nuclear antigen 1 (EBNA1); **C)** Antibodies against Zta (ZEBRA), early D
264 antigen (EAd), VCA, and EBNA1. Red depicts a strong positive correlation, and blue indicates a weak
265 correlation.

266 **Reference**

- 267 1. Coghill AE, Hildesheim A. 2014. Epstein-Barr virus antibodies and the risk of associated
268 malignancies: review of the literature. *Am J Epidemiol* 180:687-95.
- 269 2. Middeldorp JM. 2015. Epstein-Barr Virus-Specific Humoral Immune Responses in Health and
270 Disease. *Curr Top Microbiol Immunol* 391:289-323.
- 271 3. Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, Wang YS, Su GR. 1982. Serological mass
272 survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. *Int J Cancer*
273 29:139-41.
- 274 4. Zeng Y, Zhong JM, Li LY, Wang PZ, Tang H, Ma YR, Zhu JS, Pan WJ, Liu YX, Wei ZN, et al. 1983.
275 Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County,
276 China. *Intervirology* 20:190-4.
- 277 5. Zong YS, Sham JS, Ng MH, Ou XT, Guo YQ, Zheng SA, Liang JS, Qiu H. 1992. Immunoglobulin A
278 against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the
279 nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. *Cancer* 69:3-7.
- 280 6. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS. 2001. Serologic markers of
281 Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. *N Engl J Med*
282 345:1877-82.

- 283 7. Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, Cheng WM, Zong YS, Chan KH, Ng SP, Wei WI, Chua DT,
284 Sham JS, Ng MH. 2007. Sustained elevation of Epstein-Barr virus antibody levels preceding
285 clinical onset of nasopharyngeal carcinoma. *Br J Cancer* 96:623-30.
- 286 8. Hsu WL, Chen JY, Chien YC, Liu MY, You SL, Hsu MM, Yang CS, Chen CJ. 2009. Independent effect
287 of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622
288 males without family history in Taiwan. *Cancer Epidemiol Biomarkers Prev* 18:1218-26.
- 289 9. Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, Chen F, Liu Z, Guo X, Mo H, Chen J, Rao D, Ye W,
290 Cao S, Hong M. 2012. Establishment of VCA and EBNA1 IgA-based combination by enzyme-
291 linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a
292 two-stage design with a preliminary performance study and a mass screening in southern China.
293 *Int J Cancer* 131:406-16.
- 294 10. Yu KJ, Hsu WL, Pfeiffer RM, Chiang CJ, Wang CP, Lou PJ, Cheng YJ, Gravitt P, Diehl SR, Goldstein
295 AM, Chen CJ, Hildesheim A. 2011. Prognostic utility of anti-EBV antibody testing for defining NPC
296 risk among individuals from high-risk NPC families. *Clin Cancer Res* 17:1906-14.
- 297 11. Coghill AE, Pfeiffer RM, Proietti C, Hsu WL, Chien YC, Lekieffre L, Krause L, Teng A, Pablo J, Yu KJ,
298 Lou PJ, Wang CP, Liu Z, Chen CJ, Middeldorp JM, Mulvenna JP, Bethony J, Hildesheim A, Doolan
299 DL. 2018. Identification of a novel, EBV-based antibody risk stratification signature for early
300 detection of nasopharyngeal carcinoma in Taiwan. *Clin Cancer Res* doi:10.1158/1078-0432.CCR-
301 17-1929.
- 302 12. Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM. 2009. Two-step Epstein-Barr virus
303 immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and
304 confirmation of nasopharyngeal carcinoma. *Clin Vaccine Immunol* 16:706-11.
- 305 13. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, Kusumo H, Zeng YS,
306 Schouten T, Mubarika S, Middeldorp JM. 2006. Single-assay combination of Epstein-Barr Virus
307 (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV
308 immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma
309 patients: options for field screening. *J Clin Microbiol* 44:1459-67.
- 310 14. Fachiroh J, Prasetyanti PR, Paramita DK, Prasetyawati AT, Anggrahini DW, Haryana SM,
311 Middeldorp JM. 2008. Dried-blood sampling for Epstein-Barr Virus immunoglobulin G (IgG) and
312 IgA serology in nasopharyngeal carcinoma screening. *J Clin Microbiol* 46:1374-80.
- 313 15. Hutajulu SH, Fachiroh J, Argy G, Indrasari SR, Indrawati LPL, Paramita DK, Jati TBR, Middeldorp
314 JM. 2017. Seroprevalence of IgA anti Epstein-Barr virus is high among family members of
315 nasopharyngeal cancer patients and individuals presenting with chronic complaints in head and
316 neck area. *PLoS One* 12:e0180683.
- 317 16. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, Wang YB, Jiang MK, Fang Z, Meng NN.
318 1985. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-
319 positive persons in Wuzhou City, China. *Int J Cancer* 36:545-7.
- 320 17. Liu Z, Ji MF, Huang QH, Fang F, Liu Q, Jia WH, Guo X, Xie SH, Chen F, Liu Y, Mo HY, Liu WL, Yu YL,
321 Cheng WM, Yang YY, Wu BH, Wei KR, Ling W, Lin X, Lin EH, Ye W, Hong MH, Zeng YX, Cao SM.
322 2013. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma
323 screening: results from the initial phase of a cluster randomized controlled trial in Southern
324 China. *Am J Epidemiol* 177:242-50.
- 325 18. Coghill AE, Hsu WL, Pfeiffer RM, Juwana H, Yu KJ, Lou PJ, Wang CP, Chen JY, Chen CJ, Middeldorp
326 JM, Hildesheim A. 2014. Epstein-Barr virus serology as a potential screening marker for
327 nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan. *Cancer*
328 *Epidemiol Biomarkers Prev* 23:1213-9.

- 329 19. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, Klitz W, Mack SJ, Chen IH, Hsu MM, Yang
330 CS, Brinton LA, Levine PH, Erlich HA. 2002. Association of HLA class I and II alleles and extended
331 haplotypes with nasopharyngeal carcinoma in Taiwan. *J Natl Cancer Inst* 94:1780-9.
- 332 20. Galili T. 2015. dendextend: an R package for visualizing, adjusting, and comparing trees of
333 hierarchical clustering. *Bioinformatics*. <doi:10.1093/bioinformatics/btv428>.
- 334 21. Hinkle DE, Wiersma W, SG. J. *Applied Statistics for the Behavioral Sciences*. 5th ed. Boston:
335 Houghton Mifflin; 2003.
- 336 22. Liu Z, Coghill AE, Pfeiffer RM, Proietti C, Hsu WL, Chien YC, Lekieffre L, Krause L, Yu KJ, Lou PJ,
337 Wang CP, Mulvenna J, Middeldorp JM, Bethony J, Chen CJ, Doolan DL, Hildesheim A. 2018.
338 Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the
339 Epstein-Barr Virus Proteome. *J Infect Dis* 217:1923-1931.
- 340 23. Cameron B, Flamand L, Juwana H, Middeldorp J, Naing Z, Rawlinson W, Ablashi D, Lloyd A. 2010.
341 Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in
342 post-infective fatigue syndrome. *J Med Virol* 82:1684-8.
- 343

Table 1. Summary of titer for assays testing anti-EBV antibodies.

Assay	Antigen	Antibody type	Method	Unit	Serum		Plasma	
					Median (IQR) ^a	Min-Max	Median (IQR) ^a	Min-Max
VCA								
A1	VCA-p18	IgA	ELISA	OD	4.28 (5.61)	1.25-22.58	2.41 (3.63)	0.53-17.12
A2.1	VCA	IgA	ELISA	relative OD	1.18 (2.92)	0.19-14.71	0.7 (2.15)	0.15-13.5
A2.2	VCA	IgA	ELISA	OD	0.92 (1.98)	0.19-10.8	0.66 (2.06)	0.2-11
A3 ^b	VCA	IgA	ELISA	OD	0.07 (0.16)	0.01-0.9	N/A	N/A
A4	VCA-p18	IgA	Luminex	MFI	1737 (2726.75)	15-10615	1105 (2517.25)	6-10231
A5	VCA-p18	IgA	Luminex	MFI	1682.5 (2932.5)	102-16524	1082 (2317)	45-12190
A6	VCA-p18	IgG	Luminex	MFI	11466.25 (3455.62)	1256.5-21006	13130.25 (6511.5)	1661-19609
A7	VCA-p18	IgG/IgA/IgM	Luminex	MFI	3065 (2764)	377-13253	2444 (2073.5)	164-7492
EBNA1								
A8	EBNA1	IgA	ELISA	OD	1.12 (6.6)	0.7-25.5	0.87 (4.04)	0.44-17.65
A9.1	EBNA1	IgA	ELISA	relative OD	0.44 (2.58)	0-5.07	0.25 (2.01)	0.00-5.04
A9.2 ^b	EBNA1	IgA	ELISA	OD	0.13 (1.09)	0-2.65	N/A	N/A
A10	EBNA1	IgA	Luminex	MFI	58 (1335.5)	5-1987	38 (1353.75)	35796
A11	EBNA1	IgA	Luminex	MFI	277 (1434.75)	52-4994	185.5 (1137.5)	19725
A12	EBNA1	IgA	Luminex	MFI	119 (966.88)	26-4131.5	71.5 (658.25)	30-3403
A13	EBNA1	IgG	Luminex	MFI	10569.75 (4737.62)	345-16185	10938 (7585.25)	290-17357.5

A14 ^b	EBNA1	IgG/IgA/IgM	Luminex	MFI	3109 (2162)	89-17673	N/A	N/A
A15	EBNA1	IgG/IgA/IgM	Luminex	MFI	7741.5 (3384.75)	836-17545	5816.5 (6303)	257-17412
Other								
antigens								
A16	EAd	IgA	Luminex	MFI	147 (2003.75)	1-13243	48.5 (2046.25)	1-13982
A17	EAd	IgA	Luminex	MFI	96 (75.25)	37-2654	62.75 (85.25)	29-14150
A18 ^b	EAd	IgG	Luminex	MFI	N/A	N/A	90.75 (610)	29-7846
A19 ^b	EAd	IgG/IgA/IgM	Luminex	MFI	N/A	N/A	309.5 (1518)	1-15095
A20	Zta (ZEBRA)	IgA	Luminex	MFI	30.5 (237)	1-5024	18 (537.25)	1-8591
A21 ^b	Zta (ZEBRA)	IgA	ELISA	OD	N/A	N/A	0.08 (0.11)	0.02-1.73
A22 ^b	Zta (ZEBRA)	IgG/IgA/IgM	Luminex	MFI	N/A	N/A	268.5 (892)	1-6309
A23 ^b	EA-EBNA1	IgA	ELISA	OD	N/A	N/A	N/A	N/A
A24 ^b	EA-EBNA1	IgA	ELISA	OD	N/A	N/A	N/A	N/A

Abbreviations: EBV (Epstein-Barr virus); EAd: early D antigen; EBNA1: EBV nuclear antigen 1; ELISA, enzyme-linked immunosorbent assay; MFI, median fluorescence intensity; OD, optical density; VCA: EBV capsid antigen.

a. Median level is based on 66 pooled samples.

b. Results are presented as "N/A" for assays with intraclass correlation coefficient (ICC) <0.8 or coefficients of variation (CV) >20%.

344

Table 2. Percentage agreement (Kappa) for assays detecting IgA antibodies against VCA in serum. ^a

Assay	A1	A2.1	A2.2	A3	A4	A5
A1 ^b	100	52 (N/A)	47 (N/A)	12 (N/A)	95 (N/A)	97 (N/A)
A2.1	--	100	95 (0.9)	61 (0.2)	50 (-0.03)	52 (0.002)
A2.2	--	--	100	65 (0.3)	48 (0.02)	50 (0.05)
A3	--	--	--	100	17 (0.01)	15 (0.009)
A4	--	--	--	--	100	98 (0.8)
A5	--	--	--	--	--	100

Abbreviations: VCA: Epstein-Barr virus capsid antigen.

a. Cells with duplicated information are presented as "--".

b. All samples were defined as positive by Assay A1. No Kappa value can be estimated, and results are presented as "N/A".

345

346

347

348

349

350

351

352

353

354

Table 3. Percentage agreement (Kappa) for assays measuring IgA antibodies against EBNA1 in serum. ^a

Assay	A8	A9.1	A9.2	A10	A11	A12
A8	100	67 (0.7)	76 (0.9)	73 (0.8)	62 (0.2)	68 (0.7)
A9.1	--	100	88 (0.8)	94 (0.8)	29 (0.1)	92 (0.9)
A9.2	--	--	100	94 (0.9)	41 (0.2)	89 (0.7)
A10	--	--	--	100	35 (0.2)	95 (0.7)
A11	--	--	--	--	100	30 (0.1)
A12	--	--	--	--	--	100

Abbreviations: EBNA1: Epstein-Barr virus nuclear antigen 1.

a. Cells with duplicated information are presented as "--".

355

Figure 1

